FENNEC PHARMACEUTICALS INC. Gross Profit
FENNEC PHARMACEUTICALS INC. (FENC) reported Gross Profit of $19.99 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Income Statement
us-gaap:GrossProfit · last filed 2024-03-29
- FENNEC PHARMACEUTICALS INC. gross profit for the quarter ending 2023-12-31 was $9.05M.
- FENNEC PHARMACEUTICALS INC. gross profit for the quarter ending 2023-09-30 was $6.18M.
- FENNEC PHARMACEUTICALS INC. gross profit for the quarter ending 2023-06-30 was $3.18M.
- FENNEC PHARMACEUTICALS INC. gross profit for the quarter ending 2023-03-31 was $1.58M.
- FENNEC PHARMACEUTICALS INC. gross profit for fiscal 2023 was $19.99M, a 1279.78% increase from fiscal 2022.
- FENNEC PHARMACEUTICALS INC. gross profit for fiscal 2022 was $1.45M.
| Period end | Gross Profit 3 month | Gross Profit 6 month | Gross Profit 9 month | Gross Profit 12 month |
|---|---|---|---|---|
| 2023-12-31 | $9.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $15.23M derived: sum of 2 quarters · filed 2024-03-29 | $18.41M derived: sum of 3 quarters · filed 2024-03-29 | $19.99M 10-K · filed 2024-03-29 |
| 2023-09-30 | $6.18M 10-Q · filed 2023-11-09 | $9.36M derived: sum of 2 quarters · filed 2023-11-09 | $10.94M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $3.18M 10-Q · filed 2023-08-07 | $4.76M 10-Q · filed 2023-08-07 | ||
| 2023-03-31 | $1.58M 10-Q · filed 2023-05-12 | |||
| 2022-12-31 | $1.45M 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |